383 related articles for article (PubMed ID: 19436226)
1. Serum steroid levels during 12-week intravaginal dehydroepiandrosterone administration.
Labrie F; Archer D; Bouchard C; Fortier M; Cusan L; Gomez JL; Girard G; Baron M; Ayotte N; Moreau M; Dubé R; Côté I; Labrie C; Lavoie L; Bérubé R; Bélanger P; Berger L; Gilbert L; Martel C; Balser J
Menopause; 2009; 16(5):897-906. PubMed ID: 19436226
[TBL] [Abstract][Full Text] [Related]
2. Intravaginal dehydroepiandrosterone (Prasterone), a physiological and highly efficient treatment of vaginal atrophy.
Labrie F; Archer D; Bouchard C; Fortier M; Cusan L; Gomez JL; Girard G; Baron M; Ayotte N; Moreau M; Dubé R; Côté I; Labrie C; Lavoie L; Berger L; Gilbert L; Martel C; Balser J
Menopause; 2009; 16(5):907-22. PubMed ID: 19436225
[TBL] [Abstract][Full Text] [Related]
3. Effect of intravaginal dehydroepiandrosterone (Prasterone) on libido and sexual dysfunction in postmenopausal women.
Labrie F; Archer D; Bouchard C; Fortier M; Cusan L; Gomez JL; Girard G; Baron M; Ayotte N; Moreau M; Dubé R; Côté I; Labrie C; Lavoie L; Berger L; Gilbert L; Martel C; Balser J
Menopause; 2009; 16(5):923-31. PubMed ID: 19424093
[TBL] [Abstract][Full Text] [Related]
4. Serum steroid concentrations remain within normal postmenopausal values in women receiving daily 6.5mg intravaginal prasterone for 12 weeks.
Martel C; Labrie F; Archer DF; Ke Y; Gonthier R; Simard JN; Lavoie L; Vaillancourt M; Montesino M; Balser J; Moyneur É;
J Steroid Biochem Mol Biol; 2016 May; 159():142-53. PubMed ID: 26972555
[TBL] [Abstract][Full Text] [Related]
5. Serum levels of sex steroids and metabolites following 12 weeks of intravaginal 0.50% DHEA administration.
Ke Y; Labrie F; Gonthier R; Simard JN; Bergeron D; Martel C; Vaillancourt M; Montesino M; Lavoie L; Archer DF; Balser J; Moyneur E;
J Steroid Biochem Mol Biol; 2015 Nov; 154():186-96. PubMed ID: 26291918
[TBL] [Abstract][Full Text] [Related]
6. Effect of intravaginal DHEA on serum DHEA and eleven of its metabolites in postmenopausal women.
Labrie F; Cusan L; Gomez JL; Côté I; Bérubé R; Bélanger P; Martel C; Labrie C
J Steroid Biochem Mol Biol; 2008 Sep; 111(3-5):178-94. PubMed ID: 18598765
[TBL] [Abstract][Full Text] [Related]
7. Transvaginal dehydroepiandrosterone: an unconventional proposal to deliver a mysterious androgen that has no receptor or target tissue using a strategy with a new name: hormone precursor replacement therapy (HPRT).
Buster JE
Menopause; 2009; 16(5):858-9. PubMed ID: 19574935
[No Abstract] [Full Text] [Related]
8. Effect of Intravaginal Prasterone on Sexual Dysfunction in Postmenopausal Women with Vulvovaginal Atrophy.
Labrie F; Derogatis L; Archer DF; Koltun W; Vachon A; Young D; Frenette L; Portman D; Montesino M; Côté I; Parent J; Lavoie L; Beauregard A; Martel C; Vaillancourt M; Balser J; Moyneur É;
J Sex Med; 2015 Dec; 12(12):2401-12. PubMed ID: 26597311
[TBL] [Abstract][Full Text] [Related]
9. DHEA, important source of sex steroids in men and even more in women.
Labrie F
Prog Brain Res; 2010; 182():97-148. PubMed ID: 20541662
[TBL] [Abstract][Full Text] [Related]
10. Lack of effect of intravaginal dehydroepiandrosterone (DHEA, prasterone) on the endometrium in postmenopausal women.
Portman DJ; Labrie F; Archer DF; Bouchard C; Cusan L; Girard G; Ayotte N; Koltun W; Blouin F; Young D; Wade A; Martel C; Dubé R;
Menopause; 2015 Dec; 22(12):1289-95. PubMed ID: 25968836
[TBL] [Abstract][Full Text] [Related]
11. Vaginal DHEA to treat menopause related atrophy: a review of the evidence.
Panjari M; Davis SR
Maturitas; 2011 Sep; 70(1):22-5. PubMed ID: 21733647
[TBL] [Abstract][Full Text] [Related]
12. High internal consistency and efficacy of intravaginal DHEA for vaginal atrophy.
Labrie F; Archer D; Bouchard C; Fortier M; Cusan L; Gomez JL; Girard G; Baron M; Ayotte N; Moreau M; Dubé R; Côté I; Labrie C; Lavoie L; Berger L; Martel C; Balser J
Gynecol Endocrinol; 2010 Jul; 26(7):524-32. PubMed ID: 20459349
[TBL] [Abstract][Full Text] [Related]
13. Intravaginal prasterone (DHEA) provides local action without clinically significant changes in serum concentrations of estrogens or androgens.
Labrie F; Martel C; Bérubé R; Côté I; Labrie C; Cusan L; Gomez JL
J Steroid Biochem Mol Biol; 2013 Nov; 138():359-67. PubMed ID: 23954500
[TBL] [Abstract][Full Text] [Related]
14. Effect of intravaginal dehydroepiandrosterone (DHEA) on the female sexual function in postmenopausal women: ERC-230 open-label study.
Bouchard C; Labrie F; Derogatis L; Girard G; Ayotte N; Gallagher J; Cusan L; Archer DF; Portman D; Lavoie L; Beauregard A; Côté I; Martel C; Vaillancourt M; Balser J; Moyneur E;
Horm Mol Biol Clin Investig; 2016 Mar; 25(3):181-90. PubMed ID: 26725467
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause.
Labrie F; Archer DF; Koltun W; Vachon A; Young D; Frenette L; Portman D; Montesino M; Côté I; Parent J; Lavoie L; Beauregard A; Martel C; Vaillancourt M; Balser J; Moyneur É;
Menopause; 2016 Mar; 23(3):243-56. PubMed ID: 26731686
[TBL] [Abstract][Full Text] [Related]
16. Androgens and sexual function: a placebo-controlled, randomized, double-blind study of testosterone vs. dehydroepiandrosterone in men with sexual dysfunction and androgen deficiency.
Morales A; Black A; Emerson L; Barkin J; Kuzmarov I; Day A
Aging Male; 2009 Dec; 12(4):104-12. PubMed ID: 19883295
[TBL] [Abstract][Full Text] [Related]
17. Serum steroids remain within the same normal postmenopausal values during 12-month intravaginal 0.50% DHEA.
Ke Y; Gonthier R; Simard JN; Archer D; Lavoie L; Martel C; Vaillancourt M; Labrie F
Horm Mol Biol Clin Investig; 2015 Dec; 24(3):117-29. PubMed ID: 26509785
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause.
Labrie F; Archer DF; Koltun W; Vachon A; Young D; Frenette L; Portman D; Montesino M; Côté I; Parent J; Lavoie L; BSc AB; Martel C; Vaillancourt M; Balser J; Moyneur É;
Menopause; 2018 Nov; 25(11):1339-1353. PubMed ID: 30358731
[TBL] [Abstract][Full Text] [Related]
19. Lack of influence of dyspareunia on the beneficial effect of intravaginal prasterone (dehydroepiandrosterone, DHEA) on sexual dysfunction in postmenopausal women.
Labrie F; Archer D; Bouchard C; Fortier M; Cusan L; Gomez JL; Girard G; Baron M; Ayotte N; Moreau M; Dubé R; Côté I; Labrie C; Lavoie L; Gilbert L; Martel C; Balser J
J Sex Med; 2014 Jul; 11(7):1766-85. PubMed ID: 24774442
[TBL] [Abstract][Full Text] [Related]
20. Effect of one-week treatment with vaginal estrogen preparations on serum estrogen levels in postmenopausal women.
Labrie F; Cusan L; Gomez JL; Côté I; Bérubé R; Bélanger P; Martel C; Labrie C
Menopause; 2009; 16(1):30-6. PubMed ID: 18820592
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]